Sugi Predict

Sugi Predict / Compounds / SCHEMBL6798209

SCHEMBL6798209

SCHEMBL6798209

O=C(O)c1cccc(Oc2ncccn2)c1

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.73
▸ MEN1 O00255 1/20 0.73
▸ AKR1C3 P42330 1/20 0.66
▸ GAA P10253 1/20 0.59
▸ MAPT P10636 1/20 0.59
▸ HTT P42858 1/20 0.59
▸ LOXL2 Q9Y4K0 1/20 0.56
▸ KMO O15229 1/20 0.55
▸ NR4A2 P43354 2/20 0.53
▸ MRGPRX4 Q96LA9 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ F2 P00734 1/20 0.50
▸ F10 P00742 1/20 0.50
▸ TBXAS1 P24557 1/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ RAB9A P51151 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29720129 1.00 KMT2A (0.73) KMT2AMEN1AKR1C3GAAMAPT
SCHEMBL29025509 0.87 AKR1C3 (0.62) KMT2AMEN1AKR1C3GAAMAPT
SCHEMBL30466441 0.86 AKR1C3 (0.70) KMT2AMEN1AKR1C3LOXL2KMO
SCHEMBL30576792 0.84 AKR1C3 (0.58) KMT2AMEN1AKR1C3LOXL2KMO
SCHEMBL26606519 0.84 AKR1C3 (0.58) KMT2AMEN1AKR1C3LOXL2KMO
SCHEMBL9384901 0.84 AKR1C3 (0.58) KMT2AMEN1AKR1C3LOXL2KMO
SCHEMBL30307454 0.83 AKR1C3 (0.92) KMT2AAKR1C3KMONR4A2MRGPRX4
SCHEMBL30449599 0.83 AKR1C3 (0.92) KMT2AAKR1C3KMONR4A2MRGPRX4
SCHEMBL68858 0.83 AKR1C3 (0.92) KMT2AAKR1C3KMONR4A2MRGPRX4
SCHEMBL6798334 0.82 MEN1 (0.72) KMT2AMEN1GAAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113549248-B Magnetic light stabilizer and preparation method thereof, polyurethane composition and preparation method of polyurethane composite material 万华化学（北京）有限公司 2022-07-12 — — CN claimed
CN-113549248-A Magnetic light stabilizer and preparation method thereof, polyurethane composition and preparation method of polyurethane composite material 万华化学（北京）有限公司 2021-10-26 — — CN claimed
CN-113549248-B Magnetic light stabilizer and preparation method thereof, polyurethane composition and preparation method of polyurethane composite material 万华化学（北京）有限公司 2022-07-12 — — CN disclosed
CN-113549248-A Magnetic light stabilizer and preparation method thereof, polyurethane composition and preparation method of polyurethane composite material 万华化学（北京）有限公司 2021-10-26 — — CN disclosed
US-8518916-B2 Heterocyclic derivatives as M-GLU5 antagonists RECORDATI IRELAND LIMITED (IE) 2013-08-27 — — US disclosed
US-8518916-B2 Heterocyclic derivatives as M-GLU5 antagonists RECORDATI IRELAND LIMITED (IE) 2013-08-27 — — US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
US-20090042841-A1 NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2009-02-12 — — US disclosed
US-20090042841-A1 NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2009-02-12 — — US disclosed
US-6727245-B2 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-04-27 — — US disclosed
EP-0770079-B1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2003-02-12 — — EP disclosed
US-20020107251-A1 Heterobicyclic derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-08-08 — — US disclosed
US-6426345-B1 PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-30 — — US disclosed
EP-0920867-A1 Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-06-09 — — EP disclosed
EP-0770079-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-05-02 — — EP disclosed
WO-1996001825-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK KMT2A 2502/4885MEN1 2868/4885AKR1C3 1457/4885
US-20090042841-A1 NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS GRM5, GRIK5, GRM3 KMT2A 2216/4885MEN1 754/4885AKR1C3 4553/4885
US-20020107251-A1 Heterobicyclic derivatives ARSA, ARRB1, SULT2A1 KMT2A 968/4885MEN1 2703/4885AKR1C3 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.